Chronic Inflammation Marker Associated With Disease Risk and Shorter Lifespan

by Colleen Fleiss on  November 18, 2018 at 2:44 AM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

New marker for chronic inflammation GlycA is linked to increased risk for shorter lifespan and several organ-related diseases, the findings were made using Nightingale Health's blood testing technology.
Chronic Inflammation Marker Associated With Disease Risk and Shorter Lifespan
Chronic Inflammation Marker Associated With Disease Risk and Shorter Lifespan

Chronic inflammation is currently a hot topic in health and wellness, being linked to everything from heart disease to clinical depression. In an effort to sort the facts from speculation, researchers have been diving into the links between inflammation and different disease risks. In a recent study, building on prior research linking GlycA to risk for heart disease and shorter lifespan, scientists measured GlycA from blood samples with Nightingale's technology to explore whether it can predict a wide range of diseases in the general population.

Analyzing the GlycA levels of 11,861 Finnish volunteers and their electronic health records, researchers found that increased levels of GlycA were linked to many major diseases of internal organs, such as alcoholic liver disease, chronic renal failure, heart failure and heart disease. Several of these disease links were new discoveries. The study also explored how effective GlycA measurements are at predicting and grouping patients into different risk categories for life expectancy. The results found that GlycA levels could successfully identify patients at five-fold risk of cardiovascular disease-related mortality.

"As we have seen in numerous studies with thousands of study volunteers, GlycA has considerable potential as a marker of chronic inflammation that can effectively predict disease onset and prognosis.

The findings of this paper add further evidence to support the measurement of GlycA in national biobanks, as well as its utility in future clinical applications," says Dr Peter Würtz, Scientific Director, Nightingale Health. "Looking ahead, I'm excited by the contributions Nightingale's initiative to profile 500,000 samples in the UK Biobank will make towards furthering our understanding GlycA and its relationship with chronic diseases."

Current blood tests (e.g. cholesterol tests) only measure a handful of biomarkers, whereas Nightingale's blood testing technology measures over 220 blood biomarkers from a single sample. The measurements include routinely used markers including cholesterol and glucose, as well as other blood biomarkers that can enhance disease risk prediction, including GlycA and amino acids.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

More News on:

Anti-Inflammatory Diet Inflammation Top Ten Foods That Trigger Inflammation 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive